Comprehensive performance upgrade: Baorui Biotech's T7 RNA Polymerase 3.0 redefines the new standard for nucleic acid drug IVT processes

On August 19, 2026, the world's first Phase III clinical trial of a cancer vaccine was successfully completed.

Merck and Moderna jointly announced that their personalized tumor vaccine intismeran autogene (mRNA-4157), developed in collaboration with Merck's anti-PD-1 therapy K drug (pembrolizumab), The Phase III INTerpath-001 clinical trial for adjuvant treatment of patients with stage IIB-IV melanoma who have completed complete resection achieved positive top-line results. Nucleic acid drugs such as mRNA, circRNA and saRNA are experiencing a rapid development wave. Enzymes, the core tools of in vitro transcription, as the "core raw materials" for drug production, their activity, stability, batch consistency and compliance with drug application directly determine the efficiency of nucleic acid drug process and commercialization.

As a deep cultivator in the upstream raw material field of mRNA, we always believe that excellent enzyme raw materials are repeatedly refined in real production scenarios. Previously, as the first domestic T7 RNA polymerase focusing on dsRNA control, it has completed significant technical accumulation in the low dsRNA direction and also received valuable feedback from many partners in actual processes.

Baorui Biotech has been deeply engaged in the upstream enzyme raw material market for nucleic acid drugs, strictly adhering to a rigorous quality control system. Its production, operation, and quality systems strictly follow the ISO9001 and ISO13485 quality management systems. All enzyme raw materials for the mRNA production line are produced at GMP level, and it is equipped with professional GMP clean production workshops. Several core products have completed DMF filing, and at the same time, domestic patent and PCT international patent applications are being laid out to comprehensively empower domestic and foreign pharmaceutical companies in IND and BLA drug applications.

Blockbuster new product

T7 RNA Polymerase 3.0 (GMP)

The T7 RNA polymerase 3.0 of Baorui Biology still has a strong driving ability when the magnesium ion working concentration is relatively low during transcription (e.g., 20mM), which is superior to the competing product T7, that is, the T7 RNA polymerase 3.0 has a low dependence on magnesium ions.

In the transcriptions of different lengths of linearized templates and different nucleotide types, the transcriptional product yields using T7 RNA polymerase 3.0 remained at a relatively high level.

03: The integrity of the transcription samples is high

The CE data results indicated that the transcriptional product integrity of T7 RNA polymerase 3.0 was relatively high.

04: Transcription is consistently efficient

In the transcription of two linearized templates of different lengths, T7 RNA polymerase 3.0 could achieve both continuous and efficient transcription.

05. Effectively control the generation of dsRNA

Analysis of dsRNA content: In the transcribed versions of two linearized templates of different lengths, T7 RNA polymerase 3.0 exhibited lower dsRNA content, outperforming wild-type T7 RNA polymerase (item number: The dsRNA produced by BP-E01 is reduced by 7 to 8 times. Compared with the T7 mutants of other manufacturers, it has certain advantages in controlling the production of dsRNA.

The product has good stability

After being accelerated at 37℃ for 7 days, the transcription effect of T7 RNA polymerase 3.0 still maintained a relatively high yield.

Product Information
 T7 RNA polymerase 3.0; Item Number: BP-E11

In addition to T7 RNA polymerase 3.0, Baorui Biotech has established a complete GMP enzyme raw material matrix covering the entire chain of nucleic acid drugs, including plasmid template preparation, in vitro transcription, capping and modification, and impurity removal.

It includes over a hundred types of restriction endonucleases such as BspQ I, Bsa I, and EcoR I, meeting the diverse enzymatic digestion requirements for circRNA and mRNA plasmid template linearization.

Baorui has simultaneously developed a complete set of nucleic acid drug quality control and testing products, providing a one-stop solution to the pain points of production release testing.

With the vigorous development of the global nucleic acid drug industry, the requirements for the refinement and compliance of upstream raw materials in drug regulation have been continuously upgraded. Baorui Biotech continuously improves the performance of its tool enzymes. The new generation of GGMP enzyme raw materials represented by T7 RNA polymerase 3.0 help nucleic acid drug enterprises shorten the R&D cycle and simplify the application process, and work together to promote the global commercialization of Chinese nucleic acid drugs.